[Current optimization of combined therapy for chronic obstructive pulmonary disease]

Area of Science:

• Pharmacology and Respiratory Medicine

Context:

• Chronic Obstructive Pulmonary Disease (COPD) management requires effective bronchodilators.
• Anoro Ellipta combines vilanterol (a selective β2-adrenergic agonist) and umeclidinium bromide (a muscarinic antagonist).

Purpose:

• To evaluate the clinical efficacy and safety of Anoro Ellipta in COPD patients.
• To assess the bronchodilating mechanisms and cardiac effects of the vilanterol/umeclidinium bromide combination.

Summary:

• Inhalation of Anoro Ellipta demonstrated a significant increase in forced expiratory volume in one second (FEV1) on days 1 and 24 compared to placebo.
• Umeclidinium bromide acts via competitive inhibition of acetylcholine at muscarinic receptors, while vilanterol stimulates intracellular adenylate cyclase.
• No significant clinical effects on QT interval or cardiac rhythm were observed, indicating a favorable cardiac safety profile.

Impact:

• Anoro Ellipta offers a safe and effective therapeutic option for COPD patients.
• The innovative Ellipta device ensures efficient aerosol delivery, enhancing patient convenience and treatment adherence.